nach oben

European Journal of Nuclear Medicine and Molecular Imaging

13.05.2024 | Editorial

The EANM-SNMMI guideline on the role of [18F]FDG-PET/CT in breast cancer: Important milestones and perspectives for the future

verfasst von: Elif Hindié

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging

Einloggen, um Zugang zu erhalten

Excerpt

The Joint EANM-SNMMI guideline on the role of [18F]FDG PET/CT in breast cancer (BC) of no special type (NST), previously known as invasive ductal carcinoma, is important for the nuclear medicine and oncology communities [1]. Sofia Carrilho Vaz and co-authors discuss the utility of this imaging modality in different situations, from baseline staging to assessing treatment response and recurrence. For each scenario, the level of evidence, grade of recommendation (following NICE criteria), and percentage of agreement is provided. Contemporary BC management involves a multidisciplinary approach. The inclusion of the perspectives from medical oncologists, surgeons, radiologists and radiation oncologists, in addition to nuclear medicine specialists, provides a more complete view of the clinical implications and decision-making process. …

Vaz SC, Pilkington Woll JP, Cardoso F, Groheux D, Cook GJR, Ulaner GA, Jacene H, Rubio IT, Schoones JW, Vrancken Peeters MTFD, et al. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer. Eur J Nucl Med Mol Imaging. 2024. https://doi.org/10.1007/s00259-024-06696-9CrossRefPubMed

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 Apr;4. https://doi.org/10.3322/caac.21834. Online ahead of print.

Caswell-Jin JL, Sun LP, Munoz D, Lu Y, Li Y, Huang H, Hampton JM, Song J, Jayasekera J, Schechter C, et al. Analysis of breast Cancer mortality in the US-1975 to 2019. JAMA. 2024;331(3):233–41.PubMedCrossRef

Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, Cardoso MJ, Carey LA, Dawood S, Del Mastro L, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(2):159–82.PubMedCrossRef

Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, et al. NCCN Guidelines® insights: breast Cancer, Version 4.2023. J Natl Compr Canc Netw. 2023;21(6):594–608.PubMedCrossRef

Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J, de Roquancourt A, Hamy AS, Cuvier C, Vercellino L, Hindié E. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38(3):426–35.PubMedCrossRef

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, et al. Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast Cancer. N Engl J Med. 2022;387(1):9–20.PubMedPubMedCentralCrossRef

Dayes IS, Metser U, Hodgson N, Parpia S, Eisen AF, George R, Blanchette P, Cil TD, Arnaout A, Chan A, Levine MN. Impact of ¹⁸F-Labeled Fluorodeoxyglucose Positron Emission Tomography-computed Tomography Versus Conventional staging in patients with locally advanced breast Cancer. J Clin Oncol. 2023;41(23):3909–16.PubMedCrossRef

Groheux D, Hindié E, Delord M, Giacchetti S, Hamy AS, de Bazelaire C, de Roquancourt A, Vercellino L, Toubert ME, Merlet P, Espié M. Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst. 2012;104(24):1879–87.PubMedPubMedCentralCrossRef

10.

Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo-Riedinger A, Toubeau M, Guiu S, Coutant C, Coudert B, Fumoleau P, Brunotte F. 18F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. Eur J Nucl Med Mol Imaging. 2014;41(3):428–37.PubMedCrossRef

11.

Ko H, Baghdadi Y, Love C, Sparano JA. Clinical utility of 18F-FDG PET/CT in staging localized breast Cancer before initiating Preoperative systemic therapy. J Natl Compr Canc Netw. 2020;18(9):1240–6.PubMedCrossRef

12.

Groheux D, Giacchetti S, Delord M, de Roquancourt A, Merlet P, Hamy AS, Espié M, Hindié E. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2015;42(3):377–85.PubMedCrossRef

13.

Vogsen M, Jensen JD, Christensen IY, Gerke O, Jylling AMB, Larsen LB, Braad PE, Søe KL, Bille C, Ewertz M, Hildebrandt MG. FDG-PET/CT in high-risk primary breast cancer-a prospective study of stage migration and clinical impact. Breast Cancer Res Treat. 2021;185:145–53.PubMedCrossRef

14.

Khan SA, Zhao F, Goldstein LJ, Cella D, Basik M, Golshan M, Julian TB, Pockaj BA, Lee CA, Razaq W, et al. Early local therapy for the primary site in De Novo Stage IV breast Cancer: results of a Randomized Clinical Trial (EA2108). J Clin Oncol. 2022;40(9):978–87.PubMedPubMedCentralCrossRef

15.

Chmura SJ, Winter KA, Woodward WA, Borges VF, Salama JK, Al-Hallaq HA, Matuszak M, Milano MT, Jaskowiak NT, Bandos H et al. NRG-BR002: a phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). J Clin Oncol. 2022;40(suppl 16; abstr 1007).

16.

Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, Guttmann D, Yeh R, Gelblum DY, Namakydoust A, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (consolidative use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet. 2024;403(10422):171–82.PubMedCrossRef

17.

Pusztai L, Rozenblit M, Dubsky P, Bachelot T, Kirby AM, Linderholm BK, White JR, Chmura SJ, Carey LA, Chua BH, Miller KD. De Novo Oligometastatic breast Cancer. J Clin Oncol. 2023;41(34):5237–41.PubMedCrossRef

18.

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.PubMedCrossRef

19.

Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, et al. Adjuvant capecitabine for breast Cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–59.PubMedCrossRef

20.

von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, et al. Trastuzumab Emtansine for residual invasive HER2-Positive breast Cancer. N Engl J Med. 2019;380(7):617–28.CrossRef

21.

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, et al. Event-free survival with Pembrolizumab in Early Triple-negative breast Cancer. N Engl J Med. 2022;386(6):556–67.PubMedCrossRef

22.

Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250–68.PubMedCrossRef

23.

Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, Waikar S, Whitaker T, Ah-See AK, Eremin O, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000;18(8):1676–88.PubMedCrossRef

24.

Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D, Werner M, Dose J, Jänicke F, Graeff H, Schwaiger M. Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18(8):1689–95.PubMedCrossRef

25.

Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, Ricaud M, Bourbouloux E, Doutriaux I, Clouet M, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006;24(34):5366–72.PubMedCrossRef

26.

Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK, Kim TY, et al. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer. 2011;11:452.PubMedPubMedCentralCrossRef

27.

Groheux D, Hindié E, Giacchetti S, Delord M, Hamy AS, de Roquancourt A, Vercellino L, Berenger N, Marty M, Espié M. Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med. 2012;53(2):249–54.PubMedCrossRef

28.

Humbert O, Riedinger JM, Charon-Barra C, Berriolo-Riedinger A, Desmoulins I, Lorgis V, Kanoun S, Coutant C, Fumoleau P, Cochet A, Brunotte F. Identification of biomarkers including 18FDG-PET/CT for early prediction of response to Neoadjuvant Chemotherapy in Triple-negative breast Cancer. Clin Cancer Res. 2015;21(24):5460–8.PubMedCrossRef

29.

Groheux D, Giacchetti S, Hatt M, Marty M, Vercellino L, de Roquancourt A, Cuvier C, Coussy F, Espié M, Hindié E. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment. Br J Cancer. 2013;109(5):1157–64.PubMedPubMedCentralCrossRef

30.

Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, Van Dooren V, Aktan G, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med. 2013;54(11):1862–8.PubMedCrossRef

31.

Humbert O, Cochet A, Riedinger JM, Berriolo-Riedinger A, Arnould L, Coudert B, Desmoulins I, Toubeau M, Dygai-Cochet I, Guiu S, et al. HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41(8):1525–33.PubMedCrossRef

32.

Humbert O, Berriolo-Riedinger A, Cochet A, Gauthier M, Charon-Barra C, Guiu S, Desmoulins I, Toubeau M, Dygai-Cochet I, Coutant C, et al. Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer. Eur J Nucl Med Mol Imaging. 2014;41(3):416–27.PubMedCrossRef

33.

Groheux D, Sanna A, Majdoub M, de Cremoux P, Giacchetti S, Teixeira L, Espié M, Merlet P, de Roquancourt A, Visvikis D, et al. Baseline tumor 18F-FDG uptake and modifications after 2 cycles of Neoadjuvant Chemotherapy are Prognostic of Outcome in ER+/HER2- breast Cancer. J Nucl Med. 2015;56(6):824–31.PubMedCrossRef

34.

Groheux D, Mankoff D, Espié M, Hindié E. ¹⁸F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials. Eur J Nucl Med Mol Imaging. 2016;43(5):983–93.PubMedCrossRef

35.

Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Du FL, Dupré PF, Bachelot T, Gabelle P, et al. Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study. EClinicalMedicine. 2020;28:100566.PubMedPubMedCentralCrossRef

36.

Pérez-García JM, Cortés J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B, Dalenc F, Escrivá-de-Romaní S, Calvo Martínez L, Ribelles N, et al. 3-year invasive disease-free survival with chemotherapy de-escalation using an ¹⁸F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet. 2024;403(10437):1649–59.PubMedCrossRef

37.

Hindié E, Groheux D. Pathological complete response in breast cancer. Lancet. 2015;385(9963):114.PubMedCrossRef

38.

Hildebrandt MG, Gerke O, Baun C, Falch K, Hansen JA, Farahani ZA, Petersen H, Larsen LB, Duvnjak S, Buskevica I, et al. [18F]fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed tomography (CT) in suspected recurrent breast Cancer: a prospective comparative study of dual-time-point FDG-PET/CT, contrast-enhanced CT, and Bone Scintigraphy. J Clin Oncol. 2016;34(16):1889–97.PubMedCrossRef

39.

deSouza NM, Liu Y, Chiti A, Oprea-Lager D, Gebhart G, Van Beers BE, Herrmann K, Lecouvet FE. Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer. 2018;91:153–63.PubMedCrossRef

40.

Moser R, Pfeiffer S, Cala L, Klein E, Kiechle M, Behzadi ST, Fallenberg E, Combs SE, Weber W, Borm KJ. Detecting metastatic patterns of oligometastatic breast Cancer: a comparative analysis of ¹⁸F-FDG PET/CT and conventional CT imaging. J Nucl Med. 2024 Apr;18. jnumed.123.266925. Online ahead of print.

41.

Ulaner GA, Mankoff DA, Clark AS, Fowler AM, Linden HM, Peterson LM, Dehdashti F, Kurland BF, Mortimer J, Mouabbi J, et al. Summary: Appropriate Use Criteria for Estrogen receptor-targeted PET imaging with 16α-¹⁸F-Fluoro-17β-Fluoroestradiol. J Nucl Med. 2023;64(3):351–4.PubMedCrossRef

42.

Gennari A, Brain E, De Censi A, Nanni O, Wuerstlein R, Frassoldati A, Cortes J, Rossi V, Palleschi M, Alberini JL et al. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): Pilot study with 18F-Fluoroestradiol (18F-FES) CT/PET. Ann Oncol. 2024 Feb 27:S0923-7534(24)00057 – 7. https://doi.org/10.1016/j.annonc.2024.02.007. Online ahead of print.

43.

Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra PH, Peterson LM, Schubert EK, Dunnwald LK, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24(18):2793–9.PubMedCrossRef

44.

Mileva M, de Vries EGE, Guiot T, Wimana Z, Deleu AL, Schröder CP, Lefebvre Y, Paesmans M, Stroobants S, Huizing M, et al. Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial). NPJ Breast Cancer. 2024;10(1):4.PubMedPubMedCentralCrossRef

45.

Altena R, Burén SA, Blomgren A, Karlsson E, Tzortzakakis A, Brun N, Moein MM, Jussing E, Frejd FY, Bergh J, et al. Human epidermal growth factor receptor 2 (HER2) PET imaging of HER2-Low breast Cancer with [⁶⁸Ga]Ga-ABY-025: results from a pilot study. J Nucl Med. 2024;65(5):700–7.PubMedCrossRef

46.

Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Kalinsky K, Cortés J, Shaughnessy JO et al. Final results from the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-negative breast Cancer and association of outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 expression. J Clin Oncol 2024 Feb 29:JCO2301409. https://doi.org/10.1200/JCO.23.01409. Online ahead of print.

47.

Morgat C, MacGrogan G, Brouste V, Vélasco V, Sévenet N, Bonnefoi H, Fernandez P, Debled M, Hindié E. Expression of gastrin-releasing peptide receptor in breast Cancer and its Association with Pathologic, Biologic, and clinical parameters: a study of 1,432 primary tumors. J Nucl Med. 2017;58(9):1401–7.PubMedCrossRef

48.

Andryszak N, Świniuch D, Wójcik E, Ramlau R, Ruchała M, Czepczyński R. Head-to-Head comparison of [¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT in patients with triple-negative breast Cancer. Cancers (Basel). 2024;16(3):667.PubMedCrossRef

49.

Ulaner GA, Jhaveri K, Chandarlapaty S, Hatzoglou V, Riedl CC, Lewis JS, Mauguen A. Head-to-head evaluation of ¹⁸F-FES and ¹⁸F-FDG PET/CT in metastatic invasive lobular breast Cancer. J Nucl Med. 2021;62(3):326–31.PubMedPubMedCentralCrossRef

50.

Sahin E, Kus T, Aytekin A, Uzun E, Elboga U, Yilmaz L, Cayirli YB, Okuyan M, Cimen V, Cimen U. ⁶⁸Ga-FAPI PET/CT as an alternative to ¹⁸F-FDG PET/CT in the imaging of invasive lobular breast carcinoma. J Nucl Med. 2024;65(4):512–9.PubMedCrossRef

Titel: The EANM-SNMMI guideline on the role of [18F]FDG-PET/CT in breast cancer: Important milestones and perspectives for the future
verfasst von: Elif Hindié
Publikationsdatum: 13.05.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-024-06758-y

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The EANM-SNMMI guideline on the role of [18F]FDG-PET/CT in breast cancer: Important milestones and perspectives for the future

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten